Why Is SUMMIT THERAPEUTICS (SMMT) Stock Down Today?

Why SMMT stock is down today

Summit Therapeutics (SMMT) fell 8.61% to $13.69 in morning trading on July 24, 2026, after opening with a 5.1% gap down. The sharp decline followed a mixed update on the clinical progress of its lead candidate, ivonescimab, and a warning that current cash reserves may not last for the next 12 months. The stock traded as low as $13.20 before stabilizing slightly.

What Happened

The company outlined its November 14, 2026, FDA PDUFA date for the BLA of ivonescimab during its Q2 2026 earnings call on July 23. While the drug continues to show consistent survival benefits in global Phase III NSCLC trials, the cash flow situation raised concerns. Summit disclosed that its current financial position could impact its ability to continue operations, triggering a "going concern" risk. The firm also announced a $380 million ATM equity program to raise capital. These developments contributed to the sharp sell-off, despite Cantor Fitzgerald reiterating an Overweight rating and Stifel and Guggenheim lowering their price targets to $38.

What The Data Shows

The intraday session showed a volatile start, with the stock peaking at $14.42 before falling to a low of $13.20. Volume of 2.4 million shares was above the 3-month average. Over the last eight sessions, the stock had declined 1.2% from $15.34 to $15.15. Recent insider transactions showed three co-CEOs and the CFO buying shares in June, totaling $103.6 million in purchases. Additionally, unusual options activity included a notable call premium of $6.5 million, indicating some speculative interest.

What To Watch

Investors should monitor the November 14 FDA decision on ivonescimab and the company’s ability to execute its capital-raising initiatives. The Q3 2026 earnings report and further updates on the HARMONi-3 PFS trial will also be key for coverage and sentiment.